Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
I.JavaidS.HameedA.et al (2024)
Future treatments may increasingly integrate GLP-1 with other therapies for a holistic approach
Villardita C, Smirni P, Vecchio I
Our challenge now is effective strategies for implementation to really deliver on the promise of improving clinical outcomes for people with type 2 diabetes and CKD. Other speakers during the symposium included: Peter Rossing, MD, DMSc, Steno Diabetes Center Copenhagen, Denmark, who discussed the FLOW trial rationale
In the head-to-head SURPASS-2 trial, tirzepatide 15mg led to 5.5 kg more weight loss than semaglutide 1mg
Abrupt discontinuation of tirzepatide may provoke rebound hunger and rapid weight regain (food noise)transition should be structured and supported
US$ 24.53
US$ 22.16
US$ 26.03
US$ 27.52
US$ 29.54
US$ 23.98
US$ 24.51
US$ 21.77
